SRZN News and Press, Surrozen Inc.

2026-02-19 06:15:30 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for SRZN on February 19, 2026 11:13AM ET. SRZN was trading at $25.09 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - B...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today an...

2025-11-10 08:55:00 ET More on Surrozen Seeking Alpha’s Quant Rating on Surrozen Historical earnings data for Surrozen Financial information for Surrozen Read the full article on Seeking Alpha For further details see: Surrozen GAAP EPS of $...

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a foc...

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today a...

2025-08-11 15:12:38 ET More on Surrozen Seeking Alpha’s Quant Rating on Surrozen Historical earnings data for Surrozen Financial information for Surrozen Read the full article on Seeking Alpha For further details see: Surrozen GAAP EPS of $...

Surrozen Inc. (SRZN) is expected to report $-1.23 for Q2 2025

Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the S...

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a...